Breaking News

Financial Report: Alkermes

By Kristin Brooks | February 27, 2014

Revenues up 14% in the quarter

Alkermes

3Q Revenues: $154.5 million (+14%)

3Q Earnings: $18.1 million (+11%)

YTD Revenues: $432.9 million (+5%)

YTD Earnings: $17.6 million (-20%)

Comments: Manufacturing and royalty revenues in the quarter were $132.7 million, up 12%, driven by the atypical antipsychotic franchise, up 36% to $71.2 million. Product sales were $20.6 million, up 29% driven by and VIVITROL, with sales up 30% to $20.6 million. R&D revenues were $1.2 million, down 31%.
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors